MTMarleen Van Troys

Marleen Van Troys

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marleen Van Troys has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SImBA-SiQuAl: Advancing High-Content High-Throughput Phenotypic Profiling of 3D Microtumours

    by Elias Van De Vijver, Klara Dewitte, Axl Van Alboom, Christophe Ampe, Hans Van Vlierberghe, Marleen Van Troys

    Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research.

  • Open Access

    Pharmacological inhibition of deubiquitinase UCH-L1 by LDN57444 sensitises hepatocellular carcinoma to sorafenib by reverting drug-induced adaptive responses

    by Elias Van De Vijver, Kylian Decroix, Delphine Burggraeve, Petra Van Wassenhove, Zenzi De Vos, Christophe Ampe, Lindsey Devisscher, Hans Van Vlierberghe, Marleen Van Troys

    Background and aims Therapeutic outcomes for advanced hepatocellular carcinoma remain inadequate, despite recent advances using immunotherapy. Long-term effectiveness of systemic therapies, including second-line multi-tyrosine kinase inhibitor sorafenib, is limited by resistance mechanisms and adverse effects. Upregulated deubiquitinase UCH-L1 is frequently correlated with poor prognosis in cancers. Here, we investigated the therapeutic potential of combining pharmacological UCH-L1-inhibition with sorafenib in HCC. Methods UCH-L1 expression was analysed in TCGA-LIHC data and patient-derived HCC tissues. Sorafenib and LDN57444 effects were evaluated in vitro in cytotoxicity and invasion assays. Gene and protein expression were examined by RT-qPCR, Western blotting and immunohistochemistry. In vivo efficacy of drug synergy was assessed in an orthotopic xenograft mouse HCC model. Results In silico data-analysis revealed significantly higher UCH-L1 levels in patient HCC tumours versus non-tumour, associated with reduced overall survival. Low-dose sorafenib upregulated UCH-L1 in HCC cell line Hep3B. Paradoxically, this also promoted invasiveness and sustained MEK1/2-ERK1/2-pathway activation. Combining low-dose sorafenib with LDN57444 produced strong synergistic cytotoxicity in vitro, reverted MAPK-activation and suppressed invasion. Consistently, at low sorafenib dose co-treatment with LDN57444 completely inhibited tumour growth of Hep3B xenografts and enhanced sorafenib efficacy. Conclusion LDN57444 sensitises HCC cells to low-dose sorafenib by reverting drug-induced pro-oncogenic signalling and thereby strongly synergises with sorafenib to enhance anti-tumour efficacy in a HCC mouse model. This presents UCH-L1 as a player in treatment-induced adaptive response and supports further exploring UCH-L1-targeting in combination with sorafenib as therapeutic avenue for advanced HCC.


  • Open Access

    SImBA-SiQuAl: advancing high-content high-throughput phenotypic profiling of 3D microtumours

    by Elias Van De Vijver, Klara Dewitte, Axl Van Alboom, Christophe Ampe, Hans Van Vlierberghe, Marleen Van Troys

    SUMMARY: Three-dimensional microtumour models such as spheroids are increasingly used in cancer research as they better capture tumour architecture, growth and invasion than conventional two-dimensional cultures. However, robust and accessible tools for quantitative analysis remain limited. Here we present SImBA-SiQuAl, an integrated open-source workflow for high-throughput quantitative phenotyping of 3D spheroids and organoids. The pipeline combines SImBA, an automated image-analysis framework for performant quality-controlled image segmentation and multi-feature extraction from spheroid assays, with SiQuAl, a downstream analysis platform that automatically performs comprehensive statistical and multivariate analyses to reveal phenotypic differences between experimental conditions. In a first case study, we showcase how SImBA-SiQuAl resolves intrinsic invasion phenotypes between cancer cell lines. In a second case study, it quantifies heterogeneous responses in a spheroid drug screening assay. Together, SImBA-SiQuAl provides an effective timely tool for high-throughput, high-content microtumour phenomics in cancer research. MOTIVATION: 3D-microtumour assays such as spheroids and organoids are increasingly used in preclinical research. These assays generate rich phenotypic imaging data, but automated quantitative analysis remains a major bottleneck. This limits reproducibility, scalability, and broad adoption for large-scale, high-content phenomics studies. Moreover, it impedes comprehensively addressing biologically relevant phenotypic (heterogeneous) responses in e.g. perturbation studies. SImBA-SiQuAl ( S pheroid Im age B atch A nalysis - Si mba Qu antitative output A na l ysis) is developed to address this gap by providing an open-source, integrated workflow offering solutions in both the image processing and downstream analysis. Together, this enables in-depth quantitative analysis of 3D microtumour phenotypes across experimental settings.

  • Development of “Furan Warhead”-Equipped Antagonistic Nanobodies for Covalent Cross-Linking to the Epidermal Growth Factor Receptor

    by Laure Tack, Laia Miret-Casals, Olivier Zwaenepoel, Enrico Cadoni, Marleen Van Troys, Jan Gettemans, Annemieke Madder

    Covalent therapeutics have gained attention in drug design, as they have the potential to result in enhanced potency and prolonged duration of action. However, the safety concerns associated with off-target effects have long been a serious hurdle for covalent drug design. Proximity-enabled covalent bond formation combined with the use of caged warheads offers an attractive strategy in this context. We here report on the use of the proximity-dependent furan-oxidation-based cross-linking and a previously reported antagonistic nanobody (EgA1), to design new nanobodies that covalently trap the soluble fraction of the epidermal growth factor receptor (sEGFR). The furan-containing EgA1 nanobodies were validated for binding to serum(s)EGFR via biomolecular binding assays. Their singlet oxygen-induced cross-linking behavior toward the sEGFR protein was evaluated in vitro through photosensitizer irradiation. Initial experiments using an alternative biocompatible Rose Bengal derivative as photosensitizer further show proof of concept for the use of such furan-containing nanobodies for covalent trapping of the EGFR present on the plasma membrane of MDA-MB-231 breast cancer cells.


  • Open Access

    A short amphipathic peptide-based injectable hydrogel with antibacterial properties

    by Dorien Aerssens, Atiruj Theppawong, Hue Vu, Petra Rigole, Marleen Van Troys, Tom Coenye, Richard Hoogenboom, Steven Ballet, Charlotte Martin, Annemieke Madder

    Hydrogel materials have gained considerable interest to be used as aids in the healing of chronic and traumatic wounds, in view of their tunable mechanical stability, biocompatibility and biodegradability. Here, we describe the development of a new injectable and antibacterial peptide-based hydrogel that is composed of only nine natural amino acids. By covalently merging a short antibacterial peptide sequence with a short hydrogelator peptide sequence, the biologically active sequence H-RWRWQFQFK-NH2 was prepared, which self-assembled into a thixotropic hydrogel, a so-called ‘biogel’. This biogel and a related co-formulation of the short antimicrobial peptide H-RWRW-NH2 with the hydrogelating hexamer H-FQFQFK-NH2 were evaluated as potential wound dressings by means of an in vitro wound model using S. aureus, A. baumannii or P. aeruginosa. The obtained data showed that both the biogel and the co-formulation strategy appeared to be particularly effective towards A. baumannii and P. aeruginosa.


  • Furan warheads for covalent trapping of weak protein–protein interactions: cross-linking of thymosin β4 to actin

    by Laia Miret-Casals, Willem Vannecke, Kurt Hoogewijs, Gianluca Arauz-Garofalo, Marina Gay, Mireia Díaz-Lobo, Marta Vilaseca, Christophe Ampe, Marleen Van Troys, Annemieke Madder

    We describe furan as a triggerable ‘warhead’ for site-specific cross-linking using the actin and thymosin β4 (Tβ4)-complex as model of a weak and dynamic protein–protein interaction (PPI) with known 3D structure and with application potential in disease contexts. The identified cross-linked residues demonstrate that lysine is a target for the furan warhead. The presented in vitro validation of covalently acting ‘furan-armed’ Tβ4-variants provides initial proof to further exploit furan-technology for covalent drug design targeting lysines.


  • Open Access

    Community standards for open cell migration data

    by Alejandra N Gonzalez-Beltran, Paola Masuzzo, Christophe Ampe, Gert-Jan Bakker, Sébastien Besson, Robert H Eibl, Peter Friedl, Matthias Gunzer, Mark Kittisopikul, Sylvia E Le Dévédec, et al.

    Cell migration research has become a high-content field. However, the quantitative information encapsulated in these complex and high-dimensional datasets is not fully exploited owing to the diversity of experimental protocols and non-standardized output formats. In addition, typically the datasets are not open for reuse. Making the data open and Findable, Accessible, Interoperable, and Reusable (FAIR) will enable meta-analysis, data integration, and data mining. Standardized data formats and controlled vocabularies are essential for building a suitable infrastructure for that purpose but are not available in the cell migration domain. We here present standardization efforts by the Cell Migration Standardisation Organisation (CMSO), an open community-driven organization to facilitate the development of standards for cell migration data. This work will foster the development of improved algorithms and tools and enable secondary analysis of public datasets, ultimately unlocking new knowledge of the complex biological process of cell migration.


  • Open Access

    Prevalence of Cytoplasmic Actin Mutations in Diffuse Large B-Cell Lymphoma and Multiple Myeloma: A Functional Assessment Based on Actin Three-Dimensional Structures

    by Laura Witjes, Marleen Van Troys, Bruno Verhasselt, Christophe Ampe

    Mutations in actins have been linked to several developmental diseases. Their occurrence across different cancers has, however, not been investigated. Using the cBioPortal database we show that human actins are infrequently mutated in patient samples of various cancers types. Nevertheless, ranking these studies by mutational frequency suggest that some have a higher percentage of patients with ACTB and ACTG1 mutations. Within studies on hematological cancers, mutations in ACTB and ACTG1 are associated with lymphoid cancers since none have currently been reported in myeloid cancers. Within the different types of lymphoid cancers ACTB mutations are most frequent in diffuse large B-cell lymphoma (DLBCL) and ACTG1 mutations in multiple myeloma. We mapped the ACTB and ACTG1 mutations found in these two cancer types on the 3D-structure of actin showing they are in regions important for actin polymer formation or binding to myosin. The potential effects of the mutations on actin properties imply that mutations in cytoplasmic actins deserve dedicated research in DLBCL and multiple myeloma.


  • A new evolutionary model for the vertebrate actin family including two novel groups

    by Laura Witjes, Marleen Van Troys, Joël Vandekerckhove, Klaas Vandepoele, Christophe Ampe


  • Open Access

    Community Standards for Open Cell Migration Data

    by Alejandra N. Gonzalez-Beltran, Paola Masuzzo, Christophe Ampe, Gert-Jan Bakker, Sébastien Besson, Robert H. Eibl, Peter Friedl, Matthias Gunzer, Mark Kittisopikul, Sylvia E. Le Dévédec, et al.

    Cell migration research has become a high-content field. However, the quantitative information encapsulated in these complex and high-dimensional datasets is not fully exploited due to the diversity of experimental protocols and non-standardised output formats. In addition, typically the datasets are not open for reuse. Making the data open and Findable, Accessible, Interoperable, and Reusable (FAIR) will enable meta-analysis, data integration, and data mining. Standardised data formats and controlled vocabularies are essential for building a suitable infrastructure for that purpose but are not available in the cell migration domain. We here present standardisation efforts by the Cell Migration Standardisation Organization, CMSO, an open community-driven organisation to facilitate the development of standards for cell migration data. This work will foster the development of improved algorithms and tools, and enable secondary analysis of public datasets, ultimately unlocking new knowledge of the complex biological process of cell migration.